newsfilter
← Latest News
GlobeNewswire·

PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights

Rezatapopt granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of TP53 Y220C positive ovarian cancerNew England Journal of Medicine published first-in-human rezatapopt data showing